Compartmentalized Nucleic Acid Delivery for Targeted Gene Therapy

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current gene therapy methods face challenges in efficiently delivering nucleic acid molecules to specific tissues or organs without triggering systemic immune responses, causing toxicity, and achieving sustained expression of therapeutic proteins.

Innovation Solution

The method involves compartmentalizing a tissue or organ from the systemic circulation, allowing direct administration of a nucleic acid-containing agent, such as a virus, to parenchymal cells, and maintaining isolation until cellular uptake is complete, thereby minimizing systemic exposure and ensuring sustained expression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If nucleic acid molecules are administered systemically for gene therapy, then therapeutic effect can be achieved, but systemic toxicity and immune responses occur

Engineering Contradiction:
Improvetherapeutic effectVSAvoidsystemic toxicity
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies segmentation by dividing the administration process into two distinct phases: first compartmentalizing the target organ to isolate it from systemic circulation, then administering the nucleic acid locally within the compartmentalized organ. This segmentation separates the therapeutic action from systemic exposure, achieving local efficacy while avoiding systemic toxicity.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent implements local quality by creating a localized high-concentration environment of nucleic acid within the compartmentalized organ parenchyma, while the rest of the body remains exposed to minimal or no nucleic acid. This localized concentration strategy maximizes therapeutic effect at the target site while minimizing systemic harmful effects.

Inventive Principle:
Principle #3Local quality

2Reliability

If high doses of nucleic acid agents are administered to ensure cellular uptake, then gene expression can be achieved, but toxicity increases

Engineering Contradiction:
Improvegene expressionVSAvoidtoxicity
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent creates a localized high-concentration environment of nucleic acid within the compartmentalized organ parenchyma, ensuring adequate cellular uptake and gene expression at the target site without requiring high systemic doses that would cause toxicity.

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The patent uses compartmentalization as an intermediary mechanism that facilitates efficient local delivery of nucleic acid to parenchymal cells. This intermediary approach enables controlled uptake and expression while acting as a barrier against systemic distribution and associated toxicity.

Inventive Principle:
Principle #24Intermediary (Mediator)

3Manufacturing precision

If nucleic acid is administered directly to parenchyma, then targeted delivery is achieved, but systemic circulation cannot be restored

Engineering Contradiction:
Improvetargeted deliveryVSAvoidrestoration of circulation
Core Design Contradiction:
Manufacturing precisionVSEase of operation

Solution Approach 1:

The patent applies dynamics by making the compartmentalization reversible rather than permanent. The isolation of the organ from systemic circulation is maintained only during the nucleic acid administration phase, then actively reversed to restore normal blood flow. This dynamic approach enables both precise targeted delivery and subsequent restoration of physiological function.

Inventive Principle:
Principle #15Dynamics

Solution Approach 2:

The patent implements periodic action through a structured sequence: compartmentalization is applied periodically during administration, then removed periodically to restore circulation. This temporal rhythm ensures targeted delivery occurs during isolation while normal physiology is restored afterward, resolving the contradiction between precision and operational ease.

Inventive Principle:
Principle #19Periodic action

Data Source

PatentUS9821114B2Compartmentalized method of nucleic acid delivery and compositions and uses thereof
Publication Date: 2017.11.21 GLOBAL BIO THERAPEUTICS
  • US9821114B2 patent drawing
  • US9821114B2 patent drawing
  • US9821114B2 patent drawing

AI summary

Provided herein is a method of delivering nucleic acid molecules to a compartmentalized tissue or organ of a subject. Also provided herein are uses and processes for delivering a nucleic acid molecule to the parenchyma of a compartmentalized tissue or organ. The methods and uses can be used in the treatment of diseases and conditions and in industrial, agricultural and veterinary applications. Also provided herein are compositions containing an adenovirus or adeno-associated virus or other recombinant virus formulated for administration to the parenchyma of a tissue or organ.